- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03335566
An Efficacy and Safety Study of Sonazoid™ and SonoVue® in Participants With Focal Liver Lesions, Undergoing Pre- and Post-Contrast Ultrasound Imaging
October 4, 2018 updated by: GE Healthcare
A Phase 3 Multicentre, Randomised, Comparative Study of the Efficacy and Safety of the Ultrasound Contrast Agents Sonazoid™ and SonoVue® in Subjects With Focal Liver Lesions Undergoing Pre- and Post-Contrast Ultrasound Imaging
The purpose of this study is to compare the efficacy of Sonazoid™ and SonoVue® in participants with focal liver lesions (FLLs), by comparing pre-and post-contrast ultrasound examination findings with regard to various aspects of lesion diagnosis including diagnosis as benign versus malignant, specific lesion diagnosis, confidence in diagnosis, and quality of delineation of lesion-related blood vessels (from images obtained during vascular imaging) and detection of lesion presence and quality of delineation of the whole liver (from images obtained during whole liver imaging).
Study Overview
Study Type
Interventional
Enrollment (Actual)
424
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Dongcheng, Beijing, China, 100730
- Peking Union Medical College Hospital, East Campus: No.1 Shuaifuyuan Wangfujing
-
Haidan, Beijing, China, 100853
- Chinese PLA General Hospital, No. 28 Fuxing Road
-
Xicheng, Beijing, China, 100032
- Peking Union Medical College Hospital, West Campus: No. 41 Damucang Hutong
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- The First Affiliated Hospital, Sun-Yat sen University, No. 58 Zhongshan Second Road
-
Guangzhou, Guangdong, China, 510120
- The Second Affiliated Hospital of Zhongshan University, No. 107 Yanjiang West Road
-
-
Shanghai
-
Hongkou, Shanghai, China, 200080
- Shanghai First Hospital, North Campus: No. 100 Haining Road
-
Songjiang, Shanghai, China, 201620
- Shanghai First Hospital, South Campus: No.650 New Songjiang Road
-
Xuhui, Shanghai, China, 200032
- Zhongshan Hospital Fudan University, No. 180 Fenglin Road
-
Xuhui, Shanghai, China, 200040
- Shanghai Hua Shan Hospital, No. 12 Wulumuqi Middle Road
-
Xuhui, Shanghai, China, 200233
- Shanghai Sixth Hospital, No. 600 Yishan Road
-
Zhabei, Shanghai, China, 200072
- Shanghai Tenth People's Hospital, No. 301 Yanchang Middle Road
-
-
-
-
-
Seoul, Korea, Republic of, 110-744
- Seoul National University Hospital, 101, Daehak-Ro, Jongno-Gu
-
Seoul, Korea, Republic of, 137-701
- Seoul St Mary's Hospital, 222 Banpo-daero, Seocho-gu
-
-
-
-
-
Taipei, Taiwan, 100
- National Taiwan University Hospital, No. 7 Chung-Shan South Road
-
Taipei, Taiwan, 10449
- Mackay Memorial Hospital, No. 92, Sec. 2 Zhongshan N. Road
-
Taipei, Taiwan, 10650
- Cathay General Hospital, No. 280 Jen-Ai Road, Sec. 4
-
Taipei, Taiwan, 112
- Taipei Veterans General Hospital, No. 201 Shih-Pai Road, Sec. 2
-
-
Yunlin County
-
Douliu, Yunlin County, Taiwan
- National Taiwan University Hospital - Yunlin Branch, No. 579, Sec. 2 Yunlin Road
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 78 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria: Participants may be included in the study if they meet all of the following criteria:
- Participant has at least 1 untreated focal liver lesions (FLL) but =<8 lesions (excluding cysts) <10 centimeter (cm) in diameter confirmed in a diagnostic examination performed in the past month (or past 3 months if lesion is benign) that can be visualised by non- contrast-enhanced (CE) ultrasound
- Participant has had a dynamic CE-computed tomography (CE-CT) or CE-magnetic resonance imaging (CE-MRI) examination within the past month or is scheduled to have one in the month following inclusion in the study and the original images (or copies thereof) are/will be available. (This inclusion criterion does not apply for participants enrolled as training cases. Investigators will be asked to submit standard of truth/ reference diagnosis for training cases whenever possible, since the cases may be used for training and testing the blinded readers prior to the blinded read)
- Participant is a 20- to 80-year-old inpatient or outpatient referred for an ultrasound examination of the liver
- Participant is able and willing to comply with study procedures and will give their signed and dated informed consent
- The participant, if female, is either surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), postmenopausal (cessation of menses for more than 1 year), or non-lactating, or if of childbearing potential the results of a serum or urine human chorionic gonadotropin pregnancy test, performed on the day of investigational medicinal product (IMP) administration (with the result known before IMP administration), are negative
Exclusion Criteria:
- The participant has an acute clinically fatal condition (i.e., not expected to survive for at least 6 months)
- The participant has previously received Sonazoid™ or has received SonoVue® within the past 30 days
- The participant has undergone or is undergoing systemic or loco-regional chemotherapy, or radiation therapy
- The participant is participating in another clinical trial with an unregistered medicinal product, or less than 30 days have passed since completing participation in such a trial
- The participant has a history of allergies to eggs or egg products (i.e., manifested by full body rash, respiratory difficulty, oral or laryngeal swelling, hypotension or shock)
- The participant has known hypersensitivity to sulphur hexafluoride or to any of the components of SonoVue®
- The participant has undergone or plans to undergo liver biopsy or surgery within the 24 hours before or after this examination
- The participant has undergone or plans to undergo an examination with a contrast agent (i.e., iodinated x-ray contrast agent, magnetic resonance imaging (MRI) contrast agent or another ultrasound contrast agent) within the 24 hours before or after this examination
- The participant is considered to be unsuitable to participate in the study by the investigator
- The participant is known to have a right-to-left shunt, severe pulmonary hypertension (pulmonary artery pressure >90 millimeter of mercury (mmHg) or uncontrolled systemic hypertension
- The participant has a recent acute coronary syndrome or clinically unstable ischaemic cardiac disease, including: evolving or ongoing myocardial infarction, typical angina at rest within the last 7 days, significant worsening of cardiac symptoms within the last 7 days, recent coronary artery intervention or other factors suggesting clinical instability (e.g., recent deterioration of electrocardiogram [ECG], laboratory or clinical findings), acute cardiac failure, Class III/IV cardiac failure, or severe rhythm disorders
- The participant has adult respiratory distress syndrome, severe emphysema, pulmonary vasculitis, or a history of pulmonary emboli
- The participant has known thrombosis within the liver, portal, or mesenteric veins
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sonazoid™
Participants will receive single intravenous (I.V) bolus injection of Sonazoid™ 0.12 microliter (µL) microbubbles (MB)/kilogram (kg) body weight.
|
Single Dose of Sonazoid™ 0.12 µL MB/kg as I.V. injection.
|
Active Comparator: SonoVue®
Participants will receive single I.V bolus injection of SonoVue® 2.4 milliliter (mL).
|
Single Dose of SonoVue® 2.4 mL as I.V. injection.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Accuracy Improvement in Post-Contrast Versus Pre-Contrast Ultrasound (US) Examination for Diagnosis of the Target Lesion as Malignant or Benign Against the Reference Diagnosis (RD)/Standard of Truth
Time Frame: Pre-administration up to 15 minutes post-administration
|
Accuracy improvement was calculated by the number of participants with improved diagnoses from the pre-contrast diagnosis to the post-contrast diagnosis divided by the total number of participants, multiplied by 100.
Assessments were done by 3 blinded readers.
Efficacy population which included all participants who received Sonazoid™ or SonoVue®, for whom pre-contrast & post-contrast images were recorded, & for whom there was a reference standard contrast-enhanced computed tomography (CECT)/contrast-enhanced magnetic resonance imaging (CE-MRI) examination or biopsy.
|
Pre-administration up to 15 minutes post-administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Lesions Detected by Post-Contrast US Relative to Number of Lesions Detected by Pre-Contrast US (Both by Blinded Readers[BR]) and Number of Lesions Detected by Post-Contrast US (by BR) Relative to Number of Lesions Detected by RD (Investigators)
Time Frame: Pre-administration up to 15 minutes post-administration
|
For the cases that can be assessed by the blinded readers both pre- and post-contrast, differences were calculated between the Sonazoid™ and SonoVue® groups in the number of lesions detected during whole-liver imaging (post-contrast minus pre-contrast).
The differences were also calculated between the Sonazoid™ and SonoVue® groups in the number of lesions (post-contrast minus reference diagnosis) detected during whole-liver imaging.
|
Pre-administration up to 15 minutes post-administration
|
Number of Participants With Diagnostic Confidence (Evaluated by Blinded Readers) in Pre-Contrast and Post-Contrast Ultrasound Examination Results
Time Frame: Pre-administration up to 15 minutes post-administration
|
Confidence in diagnoses from the pre- and post-contrast ultrasound examinations was evaluated based on 4-point scale: 0-Unknown (cannot make a judgement on level of confidence), 1- Not confident (another examination was required), 2- Probable (Would have more confidence if another diagnostic imaging test such as MRI or CT was performed), 3- Definite (Sufficient confidence to the extent that another diagnostic imaging test such as MRI or CT was unnecessary).
|
Pre-administration up to 15 minutes post-administration
|
Percentage of Participants With Accuracy Improvement in Post-contrast Versus Pre-contrast Ultrasound Examination for Lesion-Specific Diagnoses of the Target Lesion Against the Reference Diagnosis/Standard of Truth
Time Frame: Pre-administration up to 15 minutes post-administration
|
The accuracy improvement was calculated by the number of participants with improved diagnoses from the pre-contrast diagnosis to the post-contrast diagnosis divided by the total number of participants, multiplied by 100.
Assessment was performed by 3 blinded readers.
|
Pre-administration up to 15 minutes post-administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 11, 2014
Primary Completion (Actual)
April 9, 2015
Study Completion (Actual)
April 9, 2015
Study Registration Dates
First Submitted
November 3, 2017
First Submitted That Met QC Criteria
November 3, 2017
First Posted (Actual)
November 7, 2017
Study Record Updates
Last Update Posted (Actual)
October 31, 2018
Last Update Submitted That Met QC Criteria
October 4, 2018
Last Verified
October 1, 2018
More Information
Terms related to this study
Other Study ID Numbers
- GE-045-002 (Other Identifier: GE HealthCare)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Lesions
-
Rigshospitalet, DenmarkCompletedFocal Liver Lesions | Focal Lesions in the AbdomenDenmark
-
Eisai Inc.Eisai LimitedCompletedLesions of the LiverJapan
-
Maastricht University Medical CenterKing's College London; Oslo University Hospital; Jessa Hospital; University Hospital... and other collaboratorsActive, not recruitingLiver Lesions Requiring HemihepatectomyUnited Kingdom, Netherlands, Belgium, Italy, Norway, Germany
-
BayerCompleted
-
University Hospital, ToursMinistry of Health, FranceCompletedLiver Cirrhosis | Liver Cancer | Focal Liver LesionsFrance
-
Ping LiangRecruitingFocal Liver Lesions | Contrast-enhanced UltrasoundChina
-
The Second Affiliated Hospital of Chongqing Medical...Nanfang Hospital of Southern Medical University; Eastern Hepatobiliary Surgery...Not yet recruitingFocal Liver LesionsChina
-
Sir Run Run Shaw HospitalCompletedBenign Lesions in Left LiverChina
-
Postgraduate Institute of Dental Sciences RohtakUnknownLiver Cirrhosis | Periapical LesionsIndia
-
Chinese PLA General HospitalUnknownAblation | Radiomics | Focal Liver Lesions | Ultrasonics | Intelligent DiagnosisChina
Clinical Trials on Sonazoid™
-
GE HealthcareCompleted
-
Japan Liver Oncology GroupUnknownLiver Cirrhosis | Hepatitis B | Hepatocellular Carcinoma | Hepatitis CJapan
-
Oregon Health and Science UniversityUnknown
-
Second Affiliated Hospital, School of Medicine,...Unknown
-
Institute of Liver and Biliary Sciences, IndiaCompletedHepatocellular Carcinoma | Microwave AblationIndia
-
Brigham and Women's HospitalGE HealthcareCompletedRenal Transplant RejectionUnited States
-
Thomas Jefferson UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University...CompletedLiver Diseases | Portal HypertensionUnited States
-
Chinese PLA General HospitalRecruitingEndometrial Carcinoma Stage IChina
-
Samsung Medical CenterCompletedFocal Nodular HyperplasiaKorea, Republic of
-
Thomas Jefferson UniversityNational Heart, Lung, and Blood Institute (NHLBI); GE HealthcareCompletedHeart Failure | Blood Pressure | Cardiac Catheterization | Echocardiography | Heart VentriclesUnited States